Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Net Margin (2016 - 2025)

BioCorRx's Net Margin history spans 15 years, with the latest figure at 127.28% for Q3 2025.

  • For Q3 2025, Net Margin changed N/A year-over-year to 127.28%; the TTM value through Sep 2025 reached 449.74%, up 1817377.0%, while the annual FY2024 figure was 66616.1%, 6239121.0% down from the prior year.
  • Net Margin for Q3 2025 was 127.28% at BioCorRx, up from 772.72% in the prior quarter.
  • Across five years, Net Margin topped out at 127.28% in Q3 2025 and bottomed at 34184.06% in Q1 2024.
  • The 5-year median for Net Margin is 5121.68% (2023), against an average of 8765.67%.
  • The largest annual shift saw Net Margin tumbled -3168752bps in 2024 before it soared 3355265bps in 2025.
  • A 5-year view of Net Margin shows it stood at 8839.34% in 2021, then surged by 84bps to 1408.31% in 2022, then crashed by -264bps to 5121.68% in 2023, then tumbled by -496bps to 30506.7% in 2024, then skyrocketed by 100bps to 127.28% in 2025.
  • Per Business Quant, the three most recent readings for BICX's Net Margin are 127.28% (Q3 2025), 772.72% (Q2 2025), and 631.41% (Q1 2025).